This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oelkers, W. Articles by Bahr, V. Search for Related Content PubMed PubMed Citation Articles by Oelkers, W. Articles by Bahr, V.

Hypertension, Vol 12, 462-467, Copyright © 1988 by American Heart Association

ARTICLES

Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin, and blood pressure in humans

W Oelkers, S Kleiner and V Bahr
Department of Medicine, Freie Universitat Berlin, West Germany.

To evaluate the physiological effects of human atrial natriuretic factor-(99-126) (ANF), we infused ANF, 0.1, 0.3, and 1.0 micrograms/min, or placebo for 125 minutes on different days into six sodium-deprived normal men. During the last 45 minutes of infusion, angiotensin II, 6 ng/kg/min, was infused. Blood pressure, heart rate, plasma concentrations of ANF, aldosterone, and cortisol, and plasma renin activity (PRA) were measured before and during infusion. Steady state mean plasma ANF levels during infusion were 26.2 (placebo), 68.8 (0.1 micrograms ANF/min), 221 (0.3 micrograms ANF/min), and 648 pg/ml (1.0 microgram ANF/min). Systolic blood pressure fell significantly (with 1.0 microgram ANF/min), and diastolic pressure tended to rise in a dose-dependent manner, while heart rate was unchanged. PRA and plasma aldosterone fell during ANF infusion in a dose-dependent manner (significant with 0.3 and 1.0 microgram ANF/min infused). The blood pressure-raising and aldosterone-stimulating effects of angiotensin II were blunted by ANF (significant only with 1.0 microgram ANF/min). It is concluded that effects of ANF on blood pressure and the renin- aldosterone system occur with plasma ANF levels close to the physiological range, as well as with slightly elevated ANF levels, as observed in congestive heart failure and renal insufficiency.

This article has been cited by other articles:

				P.-Y. Marie, P. M. Mertes, N. Hassan-Sebbag, N. de Talence, K. Djaballah, W. Djaballah, J. Friberg, P. Olivier, G. Karcher, F. Zannad, et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers J. Am. Coll. Cardiol., February 4, 2004; 43(3): 353 - 359. [Abstract] [Full Text] [PDF]

				P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats The role of C-type natriuretic peptide in cardiovascular medicine Eur. Heart J., June 2, 2001; 22(12): 997 - 1007. [PDF]

				R. W. Schrier and W. T. Abraham Hormones and Hemodynamics in Heart Failure N. Engl. J. Med., August 19, 1999; 341(8): 577 - 585. [Full Text] [PDF]

				N. C. Davidson, C. S. Barr, and A. D. Struthers C-Type Natriuretic Peptide : An Endogenous Inhibitor of Vascular Angiotensin-Converting Enzyme Activity Circulation, March 15, 1996; 93(6): 1155 - 1159. [Abstract] [Full Text]